{
  "id": 19740560,
  "title": "Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug",
  "url": "https://urgent.news/2026/11/13/eli-lilly-beats-novo-nordisk-to-china-approval-for-first-oral-glp-1-19740560",
  "topic": "world",
  "section": "World",
  "published": "2026-11-13T01:01:06.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/companies/article/3374229/eli-lilly-beats-novo-nordisk-china-approval-first-oral-glp-1-weight-loss-drug"
  },
  "original_language": "en",
  "account": null,
  "summary": "China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}